Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxagen Ltd.

www.oxagen.co.uk

Latest From Oxagen Ltd.

Redx appoints new CSO and CFO

UK-based Redx Pharma has promoted Dr Richard Armer to chief scientific officer and Phil Tottey to chief financial officer.

Teijin turns to Pulmagen to plug respiratory pipeline gap

The pharmaceutical division of Teijin has acquired rights in Japan to Pulmagen Therapeutics' lead CRTh2 antagonist ADC3680, which it will develop initially for bronchial asthma.

Respiratory Cardiovascular

Wellington Partners targets €120m after €70m first closing

The European venture capital firm Wellington Partners has completed the first closing of its fourth life sciences fund with initial commitments of €70 million from investors. At €120 million, the final target size of the fund is expected to exceed that of Wellington Partners III Life Science Fund, which raised €78 million.

Cancer Switzerland

Shionogi reassured by latest clinical results for novel anti-allergic

Shionogi is pressing ahead with a planned early Phase II programme in the US for its novel anti-allergic candidate S-555739, based on recent positive results from a Japanese trial.

Respiratory Japan
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Inflammation
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oxagen Ltd.
  • Senior Management
  • Mark Payton, PhD, CEO
    Mike Perkins, MD, Dir., Drug Dev.
    Paul Foster, Head, Fin. & Admin.
  • Contact Info
  • Oxagen Ltd.
    Phone: (44) 1235 443300
    91 Milton Park
    Abingdon, OX14 4RY
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register